The Pharma Letter Podcast
The Pharma Letter Podcast provides in-depth discussion and analysis focused on key trends, companies and events in the pharmaceutical and biotech industries. Our guests come from a broad array of sectors and business functions, from early stage research in biopharmaceuticals, to patient engagement and marketing, supply chain management and life sciences investing. Podcasts are typically 20-30 minutes in length and are released approximately once every two weeks.
Episodes
30 episodes
How real-time data could transform clinical trials
In this week’s podcast, we welcome Iddo Peleg, CEO and co-founder of Yonalink, who provides insights into the current and future state of the clinical trial industry. As we move headlong into 2025, a year that appears set to be cha...
•
Season 1
•
Episode 31
•
15:14
.png)
Japanese pharma in the UK
In this episode, we’ll take a look at the role of Japanese pharmaceutical groups in the UK, with Jackie Davis, general manager at Astellas Pharma.Tokyo-headquartered Astellas (TYO: 4503) has developed a strong portfolio in urology, onco...
•
Season 1
•
Episode 30
•
19:43
How can we use AI to program antibodies?
This week, we discuss a novel AI-driven approach to drug development, and its potential to transform the treatment of cancer and autoimmune diseases.We are joined by Yanay Ofran, chief executive and founder of Israel-based Biolojic Desi...
•
Season 1
•
Episode 29
•
16:25
.png)
Breakthroughs in MASH, with 89bio CEO
This week we’re focusing on an area of clinical research that has been of great interest for a number of years, that is NASH, also known as MASH. It’s a high area of unmet medical need, with over 20 million diagnosed cases across E...
•
Season 1
•
Episode 28
•
22:19
.png)
How to develop cancer drugs faster, with Ellipses Pharma
This week we are speaking with the chief executive of British drug development company Ellipses Pharma. Founded in 2018 to create new cancer therapies, the firm is following a unique multimodal approach to clinical development, lev...
•
Season 1
•
Episode 27
•
22:50
CRO sector surges in bio revolution
In the world of outsourced clinical research, ICON is a big fish in a pond full of other increasingly big fish.In this episode of The Pharma Letter Podcast, we chat with the company’s chief commercial officer, George McMillan.Li...
•
Season 1
•
Episode 26
•
12:46
Lilly looks to lead in Alzheimer's
With an Accelerated nod for Aduhelm (aducanumab) and now full approval for Leqembi (lecanemab) in the USA, Biogen (Nasdaq: BIIB) and Eisai (TYO: ...
•
Season 1
•
Episode 24
•
17:20
AAIC preview with Eisai deputy CCO Michael Irizarry
In the runup to the annual meeting of the Alzheimer’s Association, this week we are speaking with Michael Irizarry, deputy chief clinical officer at Eisai US.At the event in July, there will be plenty to discuss, with recent new data fr...
•
Season 1
•
Episode 23
•
22:43
.jpg)
A new way to innovate, from Flagship Pioneering
Set against a backdrop of foundering confidence in biotech stocks, the success of some companies incubated by Massachusetts-based Flagship Pioneering has been remarkable.Flagship has invested billions of dollars getting startups off the...
•
Season 1
•
Episode 22
•
23:37
%20(2).jpg)
Will radical new EU regs hobble industry?
A draft of the European Commission’s ongoing review of pharmaceutical legislation has leaked, prompting a bitterly-worded reaction from drugmakers, which
•
Season 1
•
Episode 21
•
22:56
.jpg)
Galapagos update—with CEO Paul Stoffels
This week on The Pharma Letter Podcast, we are joined by Galapagos (Euronext: GLPG) chief executive Paul Stoffels.After an illustrious career as chief scientific officer at Johnson & Johnson (NYSE: JNJ), Dr Stoffels is ready for a n...
•
Season 1
•
Episode 20
•
20:15
US midterms and beyond: the outlook for pharma
The outcome of the recent midterm elections in the USA surprised many by returning a Democrat-led Senate, preventing Republicans from gaining control of the next Congress.Analysts, having expected a stronger showing for Republicans, put ...
•
Season 1
•
Episode 19
•
18:06
%20(1).jpg)
Focus on rare liver diseases, with Albireo CEO Ron Cooper
*Partnered contentIn Boston, Massachusetts, one company is now making significant headway in the development of an innovative treatment for rare pediatric liver diseases.Led by president and chief executive officer Ron ...
•
Season 1
•
Episode 18
•
16:56
%20(1).jpg)
Inflation Reduction Act: quick take
As President Joe Biden signs the Inflation Reduction Act into law, drugmakers in the USA are poring over the likely impact on drug prices, and how best to
•
Season 1
•
Episode 17
•
12:19
EQRx plots radical disruption on pricing
For years, commentators have observed that drug prices in the USA are significantly higher than elsewhere in the world. Pointing to the high levels of innovation in the USA, a country where new drugs and biologics tend to get launched f...
•
Season 1
•
Episode 16
•
32:06
Can AI find new drugs for metabolic diseases?
Interest in the potential for artificial intelligence to transform different aspects of the drug discovery and development process is at an all-time high.According to industry analyst GlobalData, the number of AI deals in pharma has dou...
•
Season 1
•
Episode 15
•
41:29
A vaccine for Alzheimer's?
With the approval of Aduhelm (aducanumab), the first new Alzheimer’s treatment in decades, people affected by dementia were given new hope that a breakthrough had finally arrived.A year later, the product is yet to gain traction in the ...
•
Season 1
•
Episode 14
•
40:42
Is there a data capture crisis in biotech?
In recent years there has been an explosion of digital tools and platforms in the life sciences industry, designed to improve processes ranging from drug discovery and development, through to registration and commercialization.As with e...
•
Season 1
•
Episode 13
•
19:34
Mastering the microbiome
Companies developing microbiome-based treatments have garnered a lot of interest recently, following many years of uncertainty over the therapeutic potential of the approach.This has led to more money from venture capitalists, and incre...
•
Season 1
•
Episode 12
•
28:59
Should US states control drug prices?
At the national level, drug pricing continues to be a hot button issue for lawmakers, drugmakers and patients in the USA.For many years, successive administrations have proposed a range of regulatory reforms designed to contain what som...
•
Season 1
•
Episode 11
•
16:57
Will decentralized clinical trials become the new standard?
This week, we look at the potential impact of decentralized clinical trials.During the The COVID-19 pandemic, we have seen increased adoption of this kind of study, as part of a general movement towards greater use of innovative digital...
•
Season 1
•
Episode 10
•
19:17
The rise of AI in drug discovery
In this podcast, we discuss an exciting new collaboration between pharmaceutical majors in the field of AI.Around the world, ever increasing investments are being made in artificial intelligence, as drugmakers spy an opportunity to driv...
•
Season 1
•
Episode 9
•
20:31
Why hasn't the world embraced Sputnik V?
In August 2020, Russia approved its homegrown coronavirus vaccine Sputnik V, months ahead of rival programs in the west.But despite the bleak pandemic outlook, there was no clamour in Europe or the USA to place orders, as scientists cri...
•
Season 1
•
Episode 8
•
27:21
Better pharma supply chains
In the early days of the coronavirus pandemic, many drugmakers saw major share price declines as investors got to grips with the likely impact on prescribing, developing medicines, and supply chain interruptions.The second half of 2020 ...
•
Season 1
•
Episode 7
•
27:22
The importance of patient empowerment in multiple sclerosis care
Patient empowerment is a hot topic in many areas of medicine. Particularly so for diseases that are more complex to manage, and present with symptoms that aren’t immediately obvious and which vary greatly among individuals.Multiple scle...
•
Season 1
•
Episode 6
•
9:50
